Abstract:BackgroundCharacterizing expression profiles of different immune checkpoint molecules are promising for personalized checkpoint inhibitory immunotherapy. Gliomas have been shown as potential targets for immune checkpoint inhibitors recently. Our study was performed to determine coexpression levels of two major B7 immune regulatory molecules programmed death ligand 1 (PD-L1) and B7-H4, both of which have been demonstrated to inhibit antitumor host immunity in gliomas.MethodsWe assessed tumor tissues from stage II–IV primary gliomas (n=505) by immunohistochemistry (IHC) for protein levels of both PD-L1 and B7-H4. Gene coexpression analysis assessing clusters based on extent of PD-L1/B7-H4 classifier genes expression were investigated in two transcriptome datasets (The Cancer Genome Atlas and Chinese Glioma Genome Atlas). In addition, levels of immune cell infiltrates were estimated with IHC and RNA-seq data for assessing the tumor immune microenvironment of PD-L1/B7-H4 subgroups.ResultsHigh expression of PD-L1 and B7-H4 in gliomas was 23% and 20%, respectively, whereas coexpression of two proteins at high levels was limited to 2% of the cases. Comparable results were seen in RNA-seq datasets where PD-L1 mRNA expression levels negatively correlated with that of B7-H4. Gene coexpression modules clustered within each grade of gliomas demonstrated lack of double-high modules (cluster with high expression of both PD-L1 and B7-H4 classifier genes). B7-H4 mRNA expression levels showed negative correlation with extent of immune cell infiltration and High-B7-H4 module gliomas (high B7-H4 but low PD-L1 classifier genes expression) had less tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). IHC assessment also showed few TILs and TAMs in High-B7-H4 subgroup gliomas.ConclusionsThe majority of gliomas express PD-L1 or B7-H4, however, coexpression of both at high levels is minimal. The high-B7-H4 patients could be considered as ‘super-cold’ gliomas with significantly deficient in TILs, suggesting that B7-H4 might inhibit T-cell trafficking into the central nervous system. This study demonstrated that PD-L1 and B7-H4 may serve as mutually compensatory immune checkpoint molecules in gliomas for immune targeted or active-specific immunotherapy. The distinct B7-H4 pathways modulating T-cell function and immune evasion in glioma patients deserved to be further explored in the future during immunotherapy.

The Co-Inhibitory Immune Checkpoint Proteins B7-H1(PD-L1) and B7-H4 in High Grade Glioma: from Bench to Bedside

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Tumor Immune Checkpoints and Their Associated Inhibitors

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Enhanced B7-H4 Expression in Gliomas with Low PD-L1 Expression Identifies Super-Cold Tumors

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

The IFN-γ/PD-L1 Axis Between T Cells and Tumor Microenvironment: Hints for Glioma Anti-Pd-1/pd-l1 Therapy.

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Research progress and challenges of the PD-1/PD-L1 axis in gliomas

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade

Role of B7 family members in glioma: Promising new targets for tumor immunotherapy

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy

Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes

Immune Landscape and Therapeutic Strategies: New Insights into PD-L1 in Tumors

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape